Malignant insulinoma: Can we predict the long-term outcomes?

Area of Science:

• Endocrinology
• Oncology
• Pathology

Background:

• Insulinomas are common functional pancreatic neuroendocrine tumors causing various symptoms.
• Current diagnostic criteria are well-defined, but predicting clinical behavior and differentiating benign from malignant insulinomas is difficult.
• Limited comparative studies exist between benign and malignant insulinomas.

Purpose of the Study:

• To review current knowledge on insulinomas, focusing on diagnostic challenges and malignant behavior.
• To highlight gaps in understanding the molecular genetics and identifying reliable markers for metastatic disease.
• To discuss potential therapeutic targets for malignant insulinoma.

Main Methods:

• Literature review of comparative studies on benign and malignant insulinomas.
• Analysis of clinical, biochemical, and histological features associated with malignancy.
• Discussion of suggested signaling pathways and molecular genetics.

Main Results:

• Short clinical history, early fasting hypoglycemia, and elevated proinsulin, insulin, and C-peptide suggest malignancy.
• Malignant tumors tend to be larger with higher mitotic count and Ki-67 activity.
• Accurate histological criteria for distinguishing benign from malignant forms are lacking.

Conclusions:

• Accurate prediction of insulinoma behavior and early differentiation between benign and malignant types remain significant challenges.
• Further research into molecular genetics is needed to identify reliable markers for metastatic disease.
• Development of targeted therapies for malignant insulinoma requires a better understanding of its pathophysiology.